Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2009, Article ID 964897, 4 pages
http://dx.doi.org/10.1155/2009/964897
Review Article

Prevention of Cardiomyopathy in Transfusion-Dependent Homozygous Thalassaemia Today and the Role of Cardiac Magnetic Resonance Imaging

First Department of Medicine, University of Athens, “Laiko” Hospital, Goudi, Athens 11527, Greece

Received 12 September 2008; Accepted 5 March 2009

Academic Editor: Paolo Rebulla

Copyright © 2009 Athanassios Aessopos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Modell, M. Khan, and M. Darlison, “Survival in β-thalassaemia major in the UK: data from the UK thalassaemia register,” The Lancet, vol. 355, no. 9220, pp. 2051–2052, 2000. View at Google Scholar
  2. C. Borgna-Pignatti, S. Rigolotto, P. De Stefano et al., “Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine,” Haematologica, vol. 89, no. 10, pp. 1187–1193, 2004. View at Google Scholar
  3. J. J. Caro, A. Ward, T. C. Green et al., “Impact of thalassemia major on patients and their families,” Acta Haematologica, vol. 107, no. 3, pp. 150–157, 2002. View at Publisher · View at Google Scholar
  4. A. Aessopos, D. Farmakis, A. Hatziliami et al., “Cardiac status in well-treated patients with thalassemia major,” European Journal of Haematology, vol. 73, no. 5, pp. 359–366, 2004. View at Publisher · View at Google Scholar · View at PubMed
  5. N. F. Olivieri, D. G. Nathan, J. H. Macmillan et al., “Survival in medically treated patients with homozygous β-thalassemia,” The New England Journal of Medicine, vol. 331, no. 9, pp. 574–578, 1994. View at Publisher · View at Google Scholar
  6. L. J. Anderson, S. Holden, B. Davis et al., “Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload,” European Heart Journal, vol. 22, no. 23, pp. 2171–2179, 2001. View at Publisher · View at Google Scholar
  7. J. C. Wood, J. M. Tyszka, S. Carson, M. D. Nelson, Jr., and T. D. Coates, “Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease,” Blood, vol. 103, no. 5, pp. 1934–1936, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. A. Aessopos, C. Fragodimitri, F. Karabatsos et al., “Cardiac magnetic resonance imaging R2 assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia,” Haematologica, vol. 92, no. 1, pp. 131–132, 2007. View at Publisher · View at Google Scholar
  9. M. A. Tanner, R. Galanello, C. Dessi et al., “Myocardial iron loading in patients with thalassemia major on deferoxamine chelation,” Journal of Cardiovascular Magnetic Resonance, vol. 8, no. 3, pp. 543–547, 2006. View at Publisher · View at Google Scholar
  10. M. J. Cunningham, E. A. Macklin, E. J. Neufeld, and A. R. Cohen, “Complications of β-thalassemia major in North America,” Blood, vol. 104, no. 1, pp. 34–39, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. A. Aessopos, A. Giakoumis, C. Fragodimitri et al., “Correlation of echocardiography parameters with cardiac magnetic resonance imaging in transfusion-dependent thalassaemia major,” European Journal of Haematology, vol. 78, no. 1, pp. 58–65, 2007. View at Publisher · View at Google Scholar · View at PubMed
  12. N. F. Olivieri and G. M. Brittenham, “Iron-chelating therapy and the treatment of thalassemia,” Blood, vol. 89, no. 3, pp. 739–761, 1997. View at Google Scholar
  13. V. Berdoukas, C. Dakin, A. Freeman, I. Fraser, A. Aessopos, and T. Bohane, “Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration,” Haematologica, vol. 90, no. 5, pp. 685–686, 2005. View at Google Scholar
  14. A. Piga, personal communications.
  15. D. H. Fitchett, D. J. Coltart, W. A. Littler et al., “Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium,” Cardiovascular Research, vol. 14, no. 12, pp. 719–724, 1980. View at Publisher · View at Google Scholar
  16. G. Barosi, E. Arbustini, A. Gavazzi, M. Grasso, and A. Pucci, “Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients,” European Journal of Haematology, vol. 42, no. 4, pp. 382–388, 1989. View at Google Scholar
  17. L. J. Anderson, S. Holden, B. Davis et al., “Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload,” European Heart Journal, vol. 22, no. 23, pp. 2171–2179, 2001. View at Publisher · View at Google Scholar
  18. J. C. Wood, C. Enriquez, N. Ghugre et al., “MRI R2 and R2 mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients,” Blood, vol. 106, no. 4, pp. 1460–1465, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. E. Voskaridou, M. Douskou, E. Terpos et al., “Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease,” British Journal of Haematology, vol. 126, no. 5, pp. 736–742, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. G. C. Ooi, P. L. Khong, G. C. F. Chan et al., “Magnetic resonance screening of iron status in transfusion-dependent β-thalassaemia patients,” British Journal of Haematology, vol. 124, no. 3, pp. 385–390, 2004. View at Publisher · View at Google Scholar
  21. N. F. Olivieri, G. M. Brittenham, S. A. M. Armstrong et al., “First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine,” Blood, vol. 86, no. 10, supplement 1, 1995, abstract no. 249a. View at Google Scholar
  22. M. A. Westwood, D. N. Firmin, M. Gildo et al., “Intercentre reproducibility of magnetic resonance T2 measurements of myocardial iron in thalassaemia,” International Journal of Cardiovascular Imaging, vol. 21, no. 5, pp. 531–538, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. N. R. Ghugre, C. M. Enriquez, T. D. Coates, M. D. Nelson, Jr., and J. C. Wood, “Improved R2 measurement in myocardial iron overload,” Journal of Magnetic Resonance Imaging, vol. 23, no. 1, pp. 9–16, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. M. A. Tanner, R. Galanello, C. Dessi et al., “A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance,” Circulation, vol. 115, no. 14, pp. 1876–1884, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. D. J. Pennell, V. Berdoukas, M. Karagiorga et al., “Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis,” Blood, vol. 107, no. 9, pp. 3738–3744, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. C.-T. Peng, K.-C. Chow, J.-H. Chen, Y.-P. Chiang, T.-Y. Lin, and C.-H. Tsai, “Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan,” European Journal of Haematology, vol. 70, no. 6, pp. 392–397, 2003. View at Publisher · View at Google Scholar
  27. M. D. Cappellini, A. Cohen, A. Piga et al., “A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia,” Blood, vol. 107, no. 9, pp. 3455–3462, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. L. J. Anderson, M. A. Westwood, S. Holden et al., “Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2 cardiovascular magnetic resonance,” British Journal of Haematology, vol. 127, no. 3, pp. 348–355, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. C. Borgna-Pignatti, M. D. Cappellini, P. De Stefano et al., “Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major,” Blood, vol. 107, no. 9, pp. 3733–3737, 2006. View at Publisher · View at Google Scholar · View at PubMed